Feeds:
Posts
Comments

Search Results for 'Acute Lymphoblastic Leukemia (ALL) '

Noam Steiner Tomer, Summer Internship, Research Assistant 1   8/11/2020   Aviva Lev-Ari, PhdD, RN, Founder & DIrector Leaders in Pharmaceutical Business Intelligence (LPBI) Group 83 Mandalay Road Newton, MA 02459     To Whom It May Concern:   It is my pleasure to write this letter of recommendation for Noam Steiner Tomer. Noam worked for […]

Read Full Post »

WordCloud Visualization of LPBI’s Top Sixteen Articles on GENOMICS by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curators: Stephen J. Williams, Aviva Lev-Ari, PhD, RN and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD Now we will do the same for Genomics Volume I so for […]

Read Full Post »

CAR T-CELL THERAPY MARKET: 2020 – 2027 G L O B A L  M A R K E T  A N A L Y S I S  A N D I N D U S T R Y  F O R E C A S T   DISCLAIMER LPBI Group’s decision to publish the Table […]

Read Full Post »

Inotuzumab Ozogamicin: Success in relapsed/refractory Acute Lymphoblastic Leukemia (ALL) Reporter: Aviva Lev-Ari, PhD, RN   About Inotuzumab Ozogamicin Inotuzumab ozogamicin is an investigational antibody-drug conjugate (ADC) comprised of a monoclonal antibody (mAb) targeting CD22,9 a cell surface antigen expressed on approximately 90 percent of B-cell malignancies,10 linked to a cytotoxic agent. When inotuzumab ozogamicin binds to the […]

Read Full Post »

WordCloud Visualization of LPBI’s Top Sixteen Articles on CANCER in eight categories and by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curator: Stephen J. Williams, PhD and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD and Aviva Lev-Ari, PhD, RN Introduction (From Cancer Volume 1): Cancer […]

Read Full Post »

Original Volume One: Genomics Orientations for Personalized Medicine NEW GENRE Volume One: Genomics Orientations for Personalized Medicine This volume has the following three parts: PART A: The eTOCs in Spanish in Audio format PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format PART C: The Editorials of the original e-Books in English in Audio format PART […]

Read Full Post »

Daniel Menzin, BSc BioMedical Engineering, expected, May 2021, Research Assistant 4, Core Applications Developer and Acting CTO https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/daniel-menzin-bsc-biomedical-engineering-expected-may-2021-research-assistant-4-core-applications-developer-and-acting-cto/   Letter of Recommendation for Daniel Menzin Written on 8/13/2020 by   Aviva Lev-Ari, PhD, RN Director & Founder https://lnkd.in/eEyn69r Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, NJ, New Delhi, Palo Alto, Philadelphia, Toronto, Newark, DE Editor-in-Chief […]

Read Full Post »

  Original Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2).   On com since 5/18/2017 http://www.amazon.com/dp/B071VQ6YYK   NEW GENRE Volume Two: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-c-e-books-on-cancer-oncology/new-genre-volume-two-cancer-therapies-metabolic-genomics-interventional-immunotherapy-and-nanotechnology-in-therapy-delivery-series-b-volume-2%ef%bf%bc/   This volume has the following three parts:   PART A: The eTOCs in Spanish in Audio format […]

Read Full Post »

Papers citing PharmaceuticalIntelligence.com Reporter: Stephen J. Williams, PhD (10 papers, 5 peer reviewed, 2 web page, 2 teaching lectures, 1 preprint) Search from years 2012 – 2018 UPDATED on 5/22/2022 Summary Peer Reviewed Yan-Fang Guan, Gai-Rui Li, Rong-Jiao Wang, Yu-Ting Yi, Ling Yang, Dan Jiang, Xiao-Ping Zhang, and Yin Peng. Application of next-generation sequencing in […]

Read Full Post »

FDA: CAR-T therapy outweigh its risks tisagenlecleucel, manufactured by Novartis of Basel – 52 out of 63 participants — 82.5% — experienced overall remissions – young patients with Leukaemia [ALL]   Reporter: Aviva Lev-Ari, PhD, RN   Basel, July 12, 2017 – Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously […]

Read Full Post »

Next »

%d bloggers like this: